PT  - JOURNAL ARTICLE
AU  - Davis, John W.
AU  - Weller, Susan C.
AU  - Porterfield, Laura
AU  - Chen, Lu
AU  - Wilkinson, Gregg
TI  - Statins May Reduce Risk of Venous Thromboembolism in Women Taking Hormone Therapy: A Case-Control Study of 250,000 Women Aged 50-64
AID  - 10.1101/2023.05.20.23290202
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.05.20.23290202
4099  - http://medrxiv.org/content/early/2023/08/10/2023.05.20.23290202.short
4100  - http://medrxiv.org/content/early/2023/08/10/2023.05.20.23290202.full
AB  - Importance Post-menopausal hormone therapy (HT) may elevate the risk of venous thromboembolism (VTE), while statin therapy may lower risk.Objective To estimate VTE risk from HT exposure with statin therapy in women 50-64 years of age.Design, Setting, Participants, Exposure & Outcomes A case-control study in a large commercially-insured database matched cases of VTE diagnoses (1:10) to controls without VTE on age+/-2 yrs. Conditional logistic regression estimated odds ratios (ORs) for recent HT exposure (any estrogen and/or progestogen within 60 days) and current statin therapy (>90 days continuous exposure) controlling for VTE risk factors, comorbidities, and coronary artery disease.Results In a comparison of cases (n=20,359) and matched controls (n=203,590), 9% (n=19,558) had recent HT exposure and 16% (n=36,238) had current/continuous statin exposure. In adjusted models, the OR for any recent HT exposure was 1.51 (95% CI: 1.43, 1.60) compared to no HT exposure. The OR for current statin therapy was 0.88 (95% CI: 0.84, 0.93). For those with HT exposure without statin therapy the OR was 1.53 (95% CI: 1.44, 1.63), for those with HT exposure with statin therapy the OR was 1.25 (95% CI: 1.10, 1.43), and for those exposed to statin therapy without HT exposure the OR was 0.89 (95% CI: 0.85, 0.94), compared those not exposed to either statin or HT. HT with statin therapy had a 18% significantly lower odds ratio than HT without statin therapy (OR=0.82, 95% CI: 0.71, 0.94). High intensity statin therapy showed greater risk reduction.Conclusion Statin therapy may reduce VTE risk associated with HT.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded in part by the Texas Academy of Family Practitioners Foundation, which played no role in the design or analysis of the study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThese data are proprietary and are not available for public viewing. Authors can be contacted with reasonable queries on specific questions they may have related to the data.